Comparison Between a Telerehabilitation Program for Urinary Incontinence Versus a Conventional Face-to-face Program

Sponsor
Centro Hospitalar De São João, E.P.E. (Other)
Overall Status
Completed
CT.gov ID
NCT05114395
Collaborator
(none)
39
2
2
5.1
19.5
3.9

Study Details

Study Description

Brief Summary

Urinary incontinence (UI) is defined as any involuntary loss of urine. It affects a significant percentage of the population, mainly female, with a prevalence of 21.4% in Portuguese women, having a negative impact on quality of life and sexual function.

About half presents with stress UI (SUI), followed by mixed UI (MUI), with isolated urgency UI being less common.

Pelvic floor rehabilitiation is a first line treatment for SUI and MUI, however, it is not yet defined which is the best treatment program or the ideal strategies to improve adherence to it.

Telerehabilitation assumed a leading role in the covid pandemic phase, although there are few studies on pelvic floor rehabilitation for UI, none in Portugal to date.

The authors aim to evaluate the effectiveness of a hybrid program of pelvic floor rehabilitation in female patients with SUI and MUI with a predominance of SUI, including consultation and face-to-face sessions complemented with telerehabilitation.

Condition or Disease Intervention/Treatment Phase
  • Other: Pelvic Floor Telerehabilitation Program
  • Other: Pelvic Floor Face-to-Face Program
N/A

Detailed Description

Randomized longitudinal study including consecutively admitted patients on pelvic floor rehabilitation consultation of the Physical Medicine and Rehabilitation Department of Centro Hospitalar São João for conservative treatment of UI.

Patients who meet the inclusion criteria and do not meet any of the exclusion criteria will be randomized one to one between the intervention group and the control group.

The intervention group includes a hybrid program of face-to-face sessions followed by sessions of video, while the control group develops the entire program in face-to-face sessions.

The effectiveness of the program will be assessed by the results in the UI-related quality of life (primary outcome); UI severity, patient's overall perception of improvement, sexual function, depression/anxiety symptoms and satisfaction and adherence to treatment (secondary outcomes).

Study Design

Study Type:
Interventional
Actual Enrollment :
39 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Single (Outcomes Assessor)
Primary Purpose:
Treatment
Official Title:
Comparison Between a Telerehabilitation Program for Urinary Incontinence Versus a Conventional Face-to-face Program: a Longitudinal Study in Pandemic Times
Actual Study Start Date :
Mar 8, 2021
Actual Primary Completion Date :
Jul 12, 2021
Actual Study Completion Date :
Aug 9, 2021

Arms and Interventions

Arm Intervention/Treatment
Experimental: Telerehabilitation Group

The intervention group includes a hybrid program of face-to-face sessions and video sessions. In the first consultation, a face-to-face one, patients will be instructed with behavioral and lifestyle measures and it will be prescribed a 12-week exercise program, including exercises to be performed three times a day and two weekly exercise sessions - three face-to-face sessions (2 initial and one at 8 weeks) and video sessions of 30 minutes, divided into 3 phases with gradual addition of exercises of increasing difficulty in terms of duration, number of repetitions and positions. In the middle of the treatment (at 6 weeks) a medical teleconsultation is performed for reassessment. In the end of the 12-week program there will also be a face-to-face consultation.

Other: Pelvic Floor Telerehabilitation Program
See experimental and active comparator arms.

Active Comparator: Face-to-Face Group

The control group develops the entire program in face-to-face consultations and exercise sessions.

Other: Pelvic Floor Face-to-Face Program
See experimental and active comparator arms.

Outcome Measures

Primary Outcome Measures

  1. Assessment of urinary incontinence related quality of life using the Portuguese Version of the King's Health Questionnaire (KHQ). [From admission to discharge of the program, up to 13 weeks.]

    The primary outcome is the assessment of urinary incontinence related quality of life using the Portuguese Version of KHQ.

Secondary Outcome Measures

  1. Assessment of UI severity. [From admission to discharge of the program, up to 13 weeks.]

    Assessment of UI severity using the International Continence Society (ICS) pad test.

  2. Evaluation of the global perception of improvement of the patient. [From admission to discharge of the program, up to 13 weeks.]

    Evaluation of the global perception of improvement of the patient using the Portuguese version of the Patient Global Impression of Improvement (PGI-I) Scale. The minimum value is 0 and the maximum is 10. A higher score means a better outcome.

  3. Evaluation of sexual function. [From admission to discharge of the program, up to 13 weeks.]

    Evaluation of sexual function using the Portuguese version of the Female Sexual Functioning Index (FSFI)

  4. Assessment of the presence of symptoms of depression/anxiety. [From admission to discharge of the program, up to 13 weeks.]

    Assessment of the presence of symptoms of depression/anxiety using the Portuguese version of the Hospital Anxiety & Depression Scale (HADS) questionnaire. The minimum value is 0 and the maximum is 21. A total subscale score of >8 points out of a possible 21 denotes considerable symptoms of anxiety or depression.

  5. Assessment of satisfaction with the treatment. [From admission to discharge of the program, up to 13 weeks.]

    Assessment of satisfaction with the treatment using the 9-point Likert scale. The minimum value is 1 and the maximum is 9. A higher score means a better outcome.

  6. Assessment of adherence to the treatment. [From admission to discharge of the program, up to 13 weeks.]

    Assessment of adherence to the treatment including compliance to the exercise program (number of performed sessions) and to the behavioral measures.

  7. Assessment of UI severity. [From admission to discharge of the program, up to 16 weeks.]

    Assessment of UI severity using the Portuguese version of the International Consultation on Incontinence Questionnaire - Short Form (ICIQ-SF).

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 65 Years
Sexes Eligible for Study:
Female
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Female patients aged between 18 and 65 years with SUI or MUI with a predominance of SUI with at least 1 urinary incontinence episode per week in the last month

  • Pelvic floor muscle strength greater than or equal to 2 (modified Oxford scale)

  • Capable of understanding and executing the therapeutic program and expressing agreement to participate in the study after free and informed consent

Exclusion Criteria:
  • Patients with urgency urinary incontinence or MUI with a predominance of urgency

  • Pregnant women

  • Submitted to conservative or surgical treatment of UI in the last 12 months

  • Active urinary tract infection

  • Macroscopic hematuria

  • Neurogenic dysfunction of the lower urinary tract

  • Cognitive deficit

  • Osteoarticular, neurological or psychiatric pathologies that prevent the realization of the therapeutic program

  • Active pelvic neoplasia

  • Pelvic organ prolapse grade greater than or equal to 2

  • Impossibility of access or illiteracy to technological means (phone or computer)

  • Unavailable to attend the face-to-face program due to accessibility, schedule, economic reasons or fear of the pandemic context

Contacts and Locations

Locations

Site City State Country Postal Code
1 Physical and Rehabilitation Medicine Department - Centro Hospitalar Universitário de São João Porto Portugal 4200-319
2 Susana Cristina Alves Moreira Porto Portugal 4200-319

Sponsors and Collaborators

  • Centro Hospitalar De São João, E.P.E.

Investigators

  • Principal Investigator: Susana Moreira, Centro Hospitalar Universitário São João

Study Documents (Full-Text)

More Information

Publications

Responsible Party:
Susana Moreira, Medical Doctor, Centro Hospitalar De São João, E.P.E.
ClinicalTrials.gov Identifier:
NCT05114395
Other Study ID Numbers:
  • CE 114-21
First Posted:
Nov 10, 2021
Last Update Posted:
Nov 10, 2021
Last Verified:
Nov 1, 2021
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Susana Moreira, Medical Doctor, Centro Hospitalar De São João, E.P.E.
Additional relevant MeSH terms:

Study Results

No Results Posted as of Nov 10, 2021